Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics

Lois M. Hinman,1 Philip R. Hamann, Roslyn Wallace, Ana T. Menendez, Frederick E. Durr, and Janis Upeslacis

Medical Research Division, American Cyanamid Company, Lederle Laboratories, Pearl River, New York 10965

ABSTRACT

The calicheamicin family of antitumor antibiotics are capable of producing double-stranded DNA breaks at sub-picomolar concentrations. Their potency suggested that the calicheamicins would be excellent candidates for targeted delivery and a hydrazide prepared from the most potent and abundant of the naturally occurring derivative, γh, was linked to oxidized sugars on CT-M-01, an internalizing anti-polyporphelial mucin antibody: The conjugates retained the immunoreactivity of the unmodified antibody and were specifically cytotoxic toward antigen positive tumor cells in vitro and in vivo. Hydrazide analogues of less potent calicheamicin derivatives were also prepared and conjugated to CT-M-01. Comparison of the therapeutic efficacy of the conjugates against the MX-1 xenograft tumor implanted s.c. in nude mice showed that conjugates of derivatives missing the rhamnose, a sugar residue that is part of the DNA binding region of the drug, were not as promising as antitumor therapies. However, conjugates of two derivatives, αh, and N-acetyl-γh, in which the rhamnose residue is present but the amino sugar residue of the parent drug is either missing or modified, significantly inhibited tumor growth over a 4-fold dose range and produced long-term tumor-free survivors. Sterically hindering methyl groups adjacent to the disulfide in the linker further increased the therapeutic window of these potent conjugates.

INTRODUCTION

Over the past decade, many MoAb2 conjugates of radioisotopes, protein toxins, and cytotoxic drugs have been prepared and tested in model systems. Radiolabeled MoAbs have proven to be effective imaging agents in the clinic and are showing some promising therapeutic results for the treatment of lymphomas and leukemias (1–4). Protein toxin-MoAb conjugates (immunotoxins) are likewise progressing in clinical trials, particularly for the treatment of lymphomas (5). In contrast, clinical progress with cytotoxic drug-MoAb conjugates has been less promising, despite encouraging preclinical data (6–8). An important factor limiting the success of drug-MoAb conjugates is the relatively low potency of standard chemotherapeutics, which is further reduced by their conjugation to MoAbs (9). With most clinically used anticancer drugs, a large number of drug molecules must be taken up by each cell to achieve cell death. Poor tumor penetration, low antigen expression, and antigenic heterogeneity limit the number of MoAb-targeted drug molecules that can reach each cell (10), and with many standard drugs, that number is too low to produce clinically significant antitumor effects. In contrast, the protein toxins such as ricin, which kill cells in a catalytic manner, have been used to prepare immunotoxins (protein-MoAb conjugates) that have produced highly significant antitumor effects in vivo. However, the inherent immunogenicity of the protein toxins themselves compromises the clinical utility of immunotoxins in all except severely immunocompromised patients (11–13).

Recently, several groups have concentrated their targeting research on low molecular weight cytotoxics with potencies intermediate between the protein toxins and anticancer agents such as vincristine or Adriamycin. Preclinical evaluations of conjugates of highly potent low molecular weight cytotoxics such as the trichothecenes (14) and maytansines (15), both of which are significantly more potent than vincristine, have been reported. In our own work, we have used a new family of particularly potent anti-tumor antibiotics, the calicheamcins, which were originally identified by their impressive potency in a screen for DNA damaging agents (16). The antibiotics, isolated from a broth extract of a soil microorganism Micromonospora echinospora callicenis, were termed the calicheamicins and later were identified as members of a new class of potent endenyne containing antibiotics which includes the esperamicins, dynemycin, and neocarzinostatin (17). The binding of the most potent of the calicheamicins, γh, in the minor groove of DNA and the resulting sequence-specific DNA cleavage has been described (18, 19). The calicheamicins are relatively small molecules with molecular weights in the range of M, 1500. The small size combined with a unique mechanism of action and extreme potency suggested that the calicheamicins might be good candidates for MoAb targeting.

In this article, we describe the structure-activity profile of a series of calicheamicin analogues conjugated to the anti-PEM MoAb, CT-M-01, which binds to an internalizing antigen present on a number of solid tumor types including breast, ovarian, colon, and non-small cell lung carcinomas. The goals of these studies were 3-fold: (a) to determine the feasibility of preparing calicheamicin conjugates with antitumor activity; (b) to investigate the correlation between the potency of structural analogues of the calicheamicins and their therapeutic potential as conjugates; and (c) to test linker variations in an effort to optimize the therapeutic window for the conjugates.

MATERIALS AND METHODS

Monoclonal Antibodies. CT-M-01, also known as 7F11C7, is an internalizing IgG, that recognizes the PEM antigen, located preferentially on the cell surface of human cancerous epithelial cells. Originally developed to recognize the human milk fat globule membrane of breast carcinomas, CT-M-01 binds with high affinity to a broad spectrum of solid tumors and is internalized into its target cells after binding (20). The murine CT-M-01 and MOPC-21 used in these studies were produced and purified from tissue culture supernatants by Celltech, Ltd., United Kingdom. MOPC-21, a secreted murine myeloma IgG1, that does not bind to any mouse antigen or human xenograft tumors, was used to prepare nonbinding isotype-matched MoAb conjugates (21, 22). Lym 2, an IgG2 reactive with human B-lymphocytes, but not with solid tumor lines, was used as a negative control in the in vitro binding studies (23) and was produced and purified from tissue culture supernatants by Technicon, Inc.

Iodination of MoAbs for use in the competitive binding assays was accomplished using the diiodinated Bolton Hunter reagent, N-succinimidyl 3-(4-hydroxy-3-125I)iodoepheno)propionate, purchased from New England Nuclear. The MoAb was iodinated at pH 7.4 in phosphate buffer at a protein concentration of 1.25 mg/ml, using 5 mCi of Bolton-Hunter reagent for each 2.5 mg of protein iodinated. The labeled MoAb was purified by gel filtration chromatography and exhaustive dialysis. The specific activity of the 125I-CT-M-01 ranged from 0.3 to 0.5 μCi/μg protein and the labeling did not interfere with the antigen binding of the MoAb.

Cells and Culture Methods. An MX-1 human breast carcinoma cell line, established in this laboratory, was used as the experimental target for CT-M-01
in vitro (24). The tissue culture line was derived as a clonal isolate in agarose medium from a tumor transplant of human breast carcinoma (MX-1) growing in athymic mice. MX-1 cells were propagated in RPMI 1640 containing 5% fetal calf serum, 5 μg/ml insulin and transferrin, 5 ng/ml selenium, and 50 μg/ml gentamicin. Cultures were maintained in a humidified, 5% CO₂ incubator at 36°C and were subcultured once each week by scraping the loosely attached cells from the culture flasks. The MX-1 cells bind approximately 200,000 molecules of CT-M-01 cell in vitro, approximately 25% of which is internalized within 4 h.³ The XC rat sarcoma cell line was obtained from the Naval Biomedical Laboratory, Oakland, CA. These cells were propagated as monolayers and subcultured following dispersal with 0.25% trypsin. For in vitro cytotoxicity tests, streptomycin, 50 μg/ml and penicillin, 50 units/ml, were incorporated into the medium.

Immunoreactivity of the MoAbs and conjugates was measured by a direct radioimmunoassay comparing the competitive binding of the test sample with that of iodinated CT-M-01. For each assay, 10⁶ MX-1 cells in 0.1 ml were incubated with 0.05 ml of 4 μg/ml 125I-CT-M-01 (specific activity, ~0.3–0.5 μCi/μg) and 0.05 ml of serial 4-fold dilutions of the test samples, the highest concentration being 200 μg/ml. After a 1-h incubation, the cells were washed 3 times with Dulbecco’s PBS and transferred to fresh tubes and counted.

In Vitro Cytotoxicity Assays. To evaluate cytotoxicity in drug or conjugate samples, viable cells (10⁶/0.2 ml) were aliquoted into 15-ml test tubes which contained 0.2 ml of the sample to be tested at the appropriate concentration. Concentrations were all normalized to microgram equivalents of calicheamicin γ₁. Tubes were vortexed and incubated at 37°C for 7 min, and the pellets washed 3 times with 8 ml of medium. One ml of medium was added to each pellet, the cells were vortexed, and 0.2 ml was removed and placed in a well of a 96-well plate (2 × 10⁴ cells). These cells were incubated for 3 days, at which time 0.1 ml of supernatant was removed and replaced with 0.2 ml of [3H]thymidine in 0.1 ml of fresh medium. Incubation was resumed for an additional 24 h at which point the cells were harvested and counted. Growth inhibition curves of each drug or conjugate were plotted and the 50% inhibitory concentration values for each conjugate were compared with that of the unmodified control antibody as a relative measure of retention of immunoreactivity.

In Vivo Tests for Anti-tumor Activity. Drug and drug hydrazides were tested for antitumor activity against lymphocytic leukemia P388 in mice according to the protocol described by Geran et al. (25). As expected, the MoAb conjugates which do not recognize the murine tumors were inactive in this system and were evaluated instead for antitumor effects against human breast xenograft tumors implanted in athymic mice by procedures previously described (26). The two breast carcinomas studied were the ducal cell MX-1 and a undifferentiated MX-2, both obtained as xenograft transplants from the Division of Cancer Treatment and the Division of Cancer Prevention of the National Cancer Institute. Tumors were implanted s.c. into athymic mice and test samples were injected i.p. or i.v. at several dose levels, every 4 days for a total of 3 doses, starting 2–3 days after tumor implantation. Each test group contained 6 mice and in each test a control group of 10 mice were given injections of a volume of PBS, pH 7.4 (the conjugate vehicle), equivalent to the volume of the highest conjugate dose (usually 0.5 ml). Tumor mass was determined by measuring the tumor diameter once weekly for 35–49 days post-tumor implantation. Significant antitumor activity was defined as a sustained 58% inhibition of mean tumor mass compared with untreated controls in groups with greater than 65% survivors. A TR was defined as the MTD/MED and used as a measure of the therapeutic window for the conjugates or drugs tested.

Preparation of Thiol Hydrazides. 3-Mercapto-3-methylbutyryl hydrazide used in the preparation of the “di- methyl” hydrazides was prepared as follows: 9 ml (1.3 eq) of thiocetic acid was added to 10 g of 3,3-dimethyl acrylic acid. This mixture was heated at reflux under argon for 6 h. The excess thiocetic acid was removed under aspirator vacuum and the resultant oil was dissolved in 100 ml absolute ethanol containing 200 μl of concentrated sulfuric acid. This reaction was refluxed for 24 h before adding 16 ml of hydrazine and then for an additional 24 h under argon. The reaction mixture was concentrated and the residue was dissolved in a mixture of brine and saturated sodium bicarbonate. The product was extracted with several volumes of chloroform. The combined chloroform layers were dried with magnesium sulfate, filtered, and reduced in volume to an oil. This oil was purified by flash chromatography on silica gel with a methanol-chloroform gradient and then crystallized from chloroform-hexane to give 3-mercaptop-3-methylbutyryl hydrazide as a low-melting solid.

Calicheamicin Analogues. The γ₁, α₂μ, and α₂ calicheamicins were all isolated from the fermentation broth of _M. echinospora calichensis_ as described previously (27). The structural elucidation of these compounds, the isolation of the pseudoaglycone derivative, and the synthesis of N-acetyl calicheamicin γ₁ from calicheamicin γ₁ have been described in detail as well (28).

Hydrazide derivatives of the calicheamicins were prepared by displacement at the methyltrisulfide moiety of the analogues with the mercaptopyrrolidines described above. Preparation of the calicheamicin γ₁ hydrazide typifies this procedure: 70 mg (0.051 mmol) of calicheamicin γ₁ in 100 ml of acetonitrile at ~15°C was added to 13.2 mg (2 eq) of 3-mercapto-propionyl hydrazide in 1 ml of acetonitrile. The reaction was warmed to 4°C for 24 h, and then the solvent was removed in vacuo. The crude product was purified by flash chromatography on Merck silica gel (packed with carbon tetachloride) using a gradient of 5–15% methanol in chloroform to give 55 mg of a yellowish glass. This material can be used directly or dissolved into chloroform containing a trace of methanol and precipitated by being poured into a rapidly stirring 1:1 mixture of ether-hexane to give a white powder which can be stored indefinitely at ~15°C. The high-performance liquid chromatography retention time for this compound is 5.0 min with 41% acetonitrile/0.1 mL aqueous NH₄OAc (Zorbax ODS C-18, 4.6 mm x 25 cm column; 2 ml/min) (for calicheamicin γ₁ retention time is 5.5 min with 56% acetonitrile). Mass spectrum (FAB) is 1408 (M + H+), 1430 (M + Na+); and with added acetone, 1448 (M + 40 + H+, acetone hydrazone). The magnetic resonance magnetic (300 mHz, CD₃OD/CDCI₃) of this compound is virtually identical to the published spectrum for calicheamicin γ₁ (26) except for the following: absence of a CH₃-methyl trisulfide-resonance and a new resonance at 2.97 ppm (2H, t, J = 7 Hz, CH₂). 2.56 (2H, t, J = 7 Hz, CH₂).

Conjugation of Calicheamicin to MoAbs. The method used for the preparation of MoAbs conjugates involved reactions with carbohydrate-derived aldehydes, as previously described (29). The conjugation of all the hydrazide and dimethyl hydrazide derivatives followed a similar procedure as outlined below. MoAbs, at a concentration of 5 mg/ml in 50 mM sodium acetate buffer, pH 5.5, was oxidized at 4°C for 30 min with 12.5 mM sodium periodate (prepared freshly as a 100 mM stock in the acetate buffer). The oxidized antibody was desalted by gel filtration (PD-10 columns) and then reacted at 25°C with a 30-fold molar excess of calicheamicin γ₁ hydrazide in DMF as described below. A typical conjugation reaction mixture contained approximately 3 mg/ml protein and 1 mg/ml drug hydrazide in a mixed solvent consisting of 50 mM sodium acetate buffer, pH 5.5, containing 15% DMF. After 3 h the reaction was quenched with 5% of the reaction volume of 0.2 M NaCNBH₃ and 1% (v/v) of the reaction volume of 1 M acetic acid for 1 h. The NaCNBH₃ reduction step was included in all the experiments in this article. However, subsequent studies indicated under the conditions used in this study little, if any, reduction of the hydrazide moiety occurred and conjugates made with and without reduction showed no differences, including in biological properties. Acetylhydrazide does function in blocking unreacted free aldehyde groups and minimizing aggregation and therefore is routinely included in all aldehyde-based conjugation reactions. To terminate the conjugation reactions, conjugates were passed through a desalting column equilibrated with 50 mM phosphate buffer, 100 mM NaCl, at pH 6.5, and exhaustively dialyzed against the same buffer. Monomeric conjugates were separated from dimers and higher order aggregates by S-200 gel exclusion chromatography.

The drug concentrations of calicheamicin derivatives and drug loading on conjugates were determined spectrophotometrically. The extinction coefficient de-
temined for a calicheamicin $\gamma_1$, $\beta$-mercaptopropionic acid disulfide of 4010 $\text{m}^{-1}$ at 333 nm (in 10% DMF in PBS), a species that represents the attached disulfide form of the drug, was used as a standard. Since none of the structural modifications of the calicheamiscins described here significantly affect the chromophore of the drug, this extinction coefficient was adjusted for variations in the molecular weight of the analogues and used for all studies. The molecular weights for the hydrazide calicheamicin derivatives included in this study are: 1408 for $\gamma_1$ hydrazide, 1248 for $\alpha_2$ hydrazide, 1091 for pseudoaglycone hydrazide, 1251 for $\alpha_3$ hydrazide, 1450 for N-acetyl-$\gamma_1$ hydrazide, 1436 for $\gamma_1$ dimethyl hydrazide, and 1478 for N-acetyl-$\gamma_1$ dimethyl hydrazide. Thus, for example, for $\gamma_1$ hydrazide conjugates, drug concentration ($\mu$g/ml) = $A_{333,3333}$ (ml/mg) using $e_{333}$ (ml/mg) = 2.85 (4010/1408). The contribution to protein absorbance made by the calicheamicin at 280 nm was estimated to be 3 times the absorbance value calculated for the drug at 333 nm. Using $e_{333}$ (ml/mg) = 1.43 as the standard extinction coefficient for an IgG molecule, a corrected antibody concentration (mg/ml) was calculated as:

$$A_{280} - (3 \times A_{333}) \quad 1.43$$

These spectroscopic values proved convenient for routinely measuring drug and MoAb concentrations in the conjugates and were confirmed using radio-labeled drug and independent determinations of protein concentration using standard BioRad reagents and assay procedures.

RESULTS

Characterization of Calicheamicin Derivatives for Conjugation.

The five structural analogues of calicheamicin used in this study have been previously designated $\gamma_1$, $\alpha_2$, $\alpha_3$, N-acetyl-$\gamma_1$, and PSAG. The structures of these derivatives, described in detail elsewhere (26, 27), are shown in Fig. 1A. The core of the molecule shown in Fig. 1A, which includes the methyl trisulfide “trigger” which undergoes reduction to cause a molecular rearrangement of the enediyne bicyclic “warhead” (the part of the molecule that generates a diradical that produces double-strand DNA breaks) and the sugar/aromatic ring “backbone” is common to all five of the analogues used in these studies. Structural variations relate to the presence or absence of the rhamnose (at $R'$) and/or aminosugar (at $R''$) as indicated. The most potent “parent” compound, calicheamicin $\gamma_1$, contains both the rhamnose and the aminosugar. The $\alpha_2$ analogue is missing the rhamnose, while $\alpha_3$ is missing the aminosugar and PSAG lacks both the rhamnose and aminosugars. The fifth analogue, N-acetyl-$\gamma_1$, was prepared by acetylation of the amino sugar of $\gamma_1$ (27). The two hydrazides (“simple” and “dimethyl”) used in these studies are shown in Fig. 1B. It should be noted that the hydrazides are disulfide versions of the trisulfide “parent” compounds and were prepared from the trisulfide analogues for conjugation to MoAbs containing periodate oxidized sugars.

The anti-tumor effects of the five parent calicheamicin derivatives, along with their respective hydrazides, were compared in vivo in the P388 leukemia model (Table 1). In each experiment, the test drug was administered i.p. to normal mice carrying P388 leukemia and a comparable group of nontumored animals. The lethality of the drug in the nontumored animals was used to determine MTD. In Table 1, we report the percentage of increase in life span for each derivative at two doses: the OD that gives the greatest percentage of increase in life span in the P388 animals, and the MTD, determined in the nontumored animals. Several conclusions can be made from these data. For all five derivatives, the MTD was less than the OD. For example, the greatest increase in life span resulting from treatment with any of these derivatives was 150% for the $\alpha_2$ calicheamicin, at a dose 8-fold higher than the MTD. The potency of the hydrazides was 2-8-fold less than that of the corresponding parent compounds for all analogues. From these data it is clear that although the calicheamiscins are highly potent, toxicity limits their therapeutic efficacy as single agents against P388 leukemia. Similar dose-limiting toxicities also were seen for these calicheamicin analogues when they were studied as single agents in other murine tumors, such as B16 melanoma (30), and in the xenograft tumors as well (see below). To test the potential of these compounds as targeted agents, monomeric conjugates were prepared from each of the five hydrazide analogues. These hydrazide conjugates had drug loadings of 2 to 3 molecules of calicheamicin equivalents/MoAb molecule and retained greater than 85% of the immunoaffinity of the unmodified MoAb.

Activity and Specificity of CT-M-01-$\gamma_1$ Hydrazide Conjugates.

Calicheamicin $\gamma_1$, the calicheamicin $\gamma_1$ hydrazide, and two conjugates, a CT-M-01-$\gamma_1$ hydrazide conjugate that binds to the MX-1 cells and a nonbinding control Lyv-2-$\gamma_1$ hydrazide conjugate, were com-

### Table 1 Comparison of antitumor effects and lethality of calicheamicin analogues and hydrazides

<table>
<thead>
<tr>
<th>Derivative</th>
<th>OD (µg/kg)</th>
<th>MTD (µg/kg)</th>
<th>OD (µg/kg)</th>
<th>MTD (µg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\gamma_1$</td>
<td>5 (123)</td>
<td>1.25 (86)</td>
<td>5 (83)</td>
<td>2.5 (100)</td>
</tr>
<tr>
<td>$\alpha_2$</td>
<td>10 (150)</td>
<td>1.25 (75)</td>
<td>10 (83)</td>
<td>5 (83)</td>
</tr>
<tr>
<td>$\alpha_3$</td>
<td>40 (109)</td>
<td>20 (73)</td>
<td>40 (73)</td>
<td>160 (73)</td>
</tr>
<tr>
<td>N-acetyl-$\gamma_1$</td>
<td>40 (123)</td>
<td>20 (79)</td>
<td>40 (63)</td>
<td>160 (63)</td>
</tr>
<tr>
<td>PSAG</td>
<td>160 (73)</td>
<td>40 (60)</td>
<td>Not tested</td>
<td></td>
</tr>
</tbody>
</table>

* Numbers in parentheses, percentages.
Conjugates produced a dose-related inhibition of tumor growth (Fig. 3). The lowest dose tested (6.3 μg/kg × 3) was nonlethal but minimally effective and a dose of 12.5 μg/kg × 3 produced a significant reduction in the size of the xenograft tumor from 21 to 35 days post-tumor implantation, with 4 out of 6 of the test animals in that dose group surviving at day 35. In this study, calicheamicin γ1, itself was lethal at one-tenth the MTD for the conjugates (MTD < 2.5 μg/kg) and the drug hydrazide and noncovalent mixture of the drug hydrazide and MoAb (prepared to simulate the concentrations of both drug and MoAb in the conjugates) were both lethal at <6.3 μg/kg. The γ1 and γ1 hydrazide were not effective at nontoxic doses and CT-M-01 itself did not inhibit the growth of the tumor at doses up to 0.5 mg/dose × 3 doses (>10 times the dose administered in this test).

From these results it was clear that conjugation of calicheamicin γ1 to CT-M-01 increased the MTD of calicheamicin γ1 more than 10-fold and, more importantly, allowed the delivery of a therapeutically effective dose of drug to the tumor. However, treatment with the CT-M-01-γ1 hydrazone conjugates did not produce any complete regressions of the MX-1 tumor or result in any long-term survivors. Based on activity against the MX-1 tumor in vivo, as presented in Fig. 3 and summarized in Table 2, a TR of ~1 could be estimated for CT-M-01-γ1 hydrazone conjugates which compares favorably with the fractional TRs of the drug derivatives or drug-MoAb mixtures. In an effort to further increase the TR for these conjugates, conjugates of other calicheamicin derivatives were also evaluated.

In Vivo Activity of CT-M-01 Conjugates of Calicheamicin Variants. Hydrazide derivatives of the four other calicheamicins described above were conjugated to CT-M-01 and tested in vivo against the MX-1 tumor. As summarized in Table 2, structural variations in the drug had a profound effect on the therapeutic efficacy of their conjugates which did not necessarily correspond with the activity of the drugs as single agents (Table 1). For example, the CT-M-01 conjugate of α2, the analogue missing the rhamnose from the putative DNA binding region of the drug and next in potency to γ1 against P388, had a TR <1 and showed no antitumor effects at nonlethal doses (Fig. 4) and the conjugates were inactive on antigen-negative xenograft tumors.

In contrast, conjugates of α3 and N-acetyl-γ1, analogues which contain the rhamnose but are modified at the amino sugar, were highly efficacious over a 4-fold dose range, showing an improved therapeutic window compared with γ1 and a TR >4 (Table 2). As shown in Fig. 5, A and B, both of these conjugates had dramatic antitumor activity, inhibiting the growth of the MX-1 tumor at nonlethal doses and producing long-term tumor-free survivors (>100 days) at the 100-μg/kg dose. The parent drug derivatives included in the tests as controls were inactive at nonlethal doses.

The fifth variant of calicheamicin conjugated to CT-M-01 was PSAG, missing both the rhamnose and the amino sugar. PSAG is significantly less potent than the other derivatives against P388 leukemia. As shown in Table 2, this conjugate was ineffective and nonlethal even at doses 28-fold higher than the MTD for the γ1 conjugate, indicating that the delivery of the "warhead" of calicheamicin on a MoAb was not sufficient to retain activity. Because of this low potency, further investigations of PSAG conjugates were not pursued.

Effects of Variations in the Hydrazone Linkage on In Vivo Activity. Changes in the linker region of the calicheamicin hydrazide conjugates were also examined as a means of increasing the TR of the calicheamicin conjugates. Methyl groups that add steric bulk adjacent to the disulfide were introduced into the hydrazide linker as shown in Fig. 2B. A comparison of the antitumor activity of a "simple" γ1 hydrazone (γ1-hyd) and a γ1-DM-hyd conjugate was made on the MX-1 tumor in vivo. As summarized in Table 2, the γ1-DM-hyd conjugate had strong antitumor activity at 6 μg/kg, a dose which is ineffective with the simple γ1-hyd conjugate (Fig. 3). In addition, no lethality was seen with the γ1-DM-hyd conjugate at the 12.5 μg/kg
doses and decreased lethality at the higher doses resulted in an increased TR for the γ1-DM-hyd over the simple γ1 hyd conjugate.

CT-M-01 conjugates of N-acetyl γ1 and α3 calicheamicins were also prepared incorporating the hindered dimethyl hydrazone linkages. A comparison of the antitumor activity of N-acetyl γ1 conjugates prepared with the simple and DM-hydrazone linkages, tested on the MX-2 breast carcinoma, is shown in Fig. 6. At both dose levels tested, the DM-hydrazone conjugate was more effective than the simple hydrazone conjugate against this tumor producing 100% tumor-free survivors at both doses. The N-acetyl γ1 and α3 conjugates, when prepared with the DM hydrazone linkage, have demonstrated significant antitumor effects with TR of four or higher and have produced long-term tumor-free survivors in a number of other antigen-positive tumor models without showing any significant activity on antigen-negative tumors. As shown in Table 2, a CT-M-01 conjugate with N-acetyl γ1-DM-hyd had a TR of >6 against the antigen-positive MX-1 tumor. An equivalent N-acetyl γ1-DM-hyd conjugate prepared with the nonbinding IgG1, MOPC-21, had a TR of <1 under comparable experimental conditions. As indicated in Table 2, the MOPC-21 conjugate showed only a slight reduction in the tumor mass at MTD (300 μg/kg × 3) and produced no tumor-free survivors. Our studies defining the activity profile of different calicheamicin derivatives conjugated with a variety of tumor-selective, internalizing MoAbs are continuing.

**DISCUSSION**

In this article we present data that demonstrate the therapeutic potential of MoAb conjugates prepared from a novel class of antitumor antibiotics, the calicheamicins. Despite the dose-limiting toxicities seen with the parent calicheamicins, modifications have been made in both the drug and the linker to produce constructs with a significant therapeutic window. These conjugates are antigen specific and have produced dose-dependent inhibition of tumor growth without lethality in all antigen-positive xenograft tumors tested. The antibody used in these studies was CT-M-01, an internalizing anti-PEM MoAb which binds to a mucin antigen abundant on a number of solid tumors including breast, non-small cell lung, ovarian and colon carcinomas. Our results with CT-M-01 conjugates as well as our previous preliminary reports suggest that internalizing antibodies act as effective surrogate carriers for potent drugs such as the calicheamicins allowing them to bypass the normal mechanisms of nonspecific drug uptake, thus rendering them less toxic (28, 31, 32).

Our efforts to optimize the targeting of the calicheamicins involved the evaluation of conjugates prepared from a number of structural analogues of the drug. Using information available on the relative potencies of various calicheamicin analogues in the P388 leukemia

---

*Unpublished results.*
the drug has remained intact while the internalizing antibody can serve to play a role as a carrier to transport the drug into cells or across membranes. The calicheamicin structure has not been established, it has been speculated that it can serve as a surrogate for the amino sugar, bringing the potent drug into the target cells. Our data suggest that an intact DNA binding region of calicheamicin is required for optimal antitumor activity, although others have reported the potent antitumor effects of certain enediyne molecules missing a DNA binding region (33).

Triggering of the enediyne is the key event in the activation of calicheamicins. Although the intracellular compartment and rate of triggering of the conjugated drug has not yet been established, the evidence so far accumulated suggests that activation through disulfide cleavage occurs after the conjugate has been internalized. Studies are in progress using radiolabeled drug and conjugates to follow the intracellular trafficking of the conjugated and unconjugated forms of the calicheamicins to explore differences in intracellular processing of the conjugated and unconjugated drug.

In addition to selecting an optimal form of the drug itself, we have improved the therapeutic potential of the calicheamicin conjugates by increasing the stability of the linker. There is significant literature precedent to suggest that the introduction of steric bulk adjacent to a thiol in disulfide-based linkers effects the stability of a conjugate in serum and modulates the ease with which drug is released at the tumor site (34–36). Preliminary studies in our laboratory have suggested that the stability of calicheamicin disulfides toward reduced glutathione is proportional to the steric bulk placed adjacent to the disulfide group. These results fit with the increased therapeutic potential seen for conjugates prepared with the dimethyl linker (37). The linkage between calicheamicin and the MoAb actually contains two possible sites for drug release: the hydrazide can be cleaved by acid hydrolysis, and the disulfide bond can be cleaved by reduction. We are currently evaluating the relative importance of these two release mechanisms.

In conclusion, we have demonstrated the potential of the calicheamicins for targeted delivery. Through the process of MoAb conjugation, we have converted a potent, yet toxic series of antibiotics into effective antitumor agents, with a significant therapeutic window for treating solid tumors. Studies are in progress to establish the activity profile of both CT-M-01 and other MoAb calicheamicin conjugates in a variety of preclinical models.

ACKNOWLEDGMENTS

We thank George Ellestad and May Lee for helpful discussions about calicheamicin chemistry. We are also grateful to Suzanne Carvajal, Dolores...
Lindt, and Lucy Colina for their help with the biological testing of the drugs and conjugates, and Martha Godwin and J. Philip James for their assistance in conjugate preparation and purification.

REFERENCES


Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics


Updated version  Access the most recent version of this article at:  
http://cancerres.aacrjournals.org/content/53/14/3336

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link  
http://cancerres.aacrjournals.org/content/53/14/3336.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.